IL276210B2 - Mers-cov vaccine - Google Patents
Mers-cov vaccineInfo
- Publication number
- IL276210B2 IL276210B2 IL276210A IL27621020A IL276210B2 IL 276210 B2 IL276210 B2 IL 276210B2 IL 276210 A IL276210 A IL 276210A IL 27621020 A IL27621020 A IL 27621020A IL 276210 B2 IL276210 B2 IL 276210B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- immunogenic composition
- fragment
- nucleic acid
- acid molecule
- Prior art date
Links
- 229940124678 MERS-CoV vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910153P | 2013-11-29 | 2013-11-29 | |
| PCT/US2014/067537 WO2015081155A1 (en) | 2013-11-29 | 2014-11-26 | Mers-cov vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL276210A IL276210A (en) | 2020-09-30 |
| IL276210B1 IL276210B1 (en) | 2023-09-01 |
| IL276210B2 true IL276210B2 (en) | 2024-01-01 |
Family
ID=53199622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276210A IL276210B2 (en) | 2013-11-29 | 2014-11-26 | Mers-cov vaccine |
| IL305392A IL305392A (en) | 2013-11-29 | 2014-11-26 | Mers-cov vaccine |
| IL245903A IL245903B (en) | 2013-11-29 | 2016-05-29 | mers-cov vaccine |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305392A IL305392A (en) | 2013-11-29 | 2014-11-26 | Mers-cov vaccine |
| IL245903A IL245903B (en) | 2013-11-29 | 2016-05-29 | mers-cov vaccine |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10016497B2 (enExample) |
| EP (1) | EP3074051A4 (enExample) |
| JP (1) | JP6412131B2 (enExample) |
| KR (2) | KR20230122181A (enExample) |
| CN (2) | CN105939730B (enExample) |
| AU (1) | AU2014354797C1 (enExample) |
| CA (1) | CA2932055A1 (enExample) |
| IL (3) | IL276210B2 (enExample) |
| SA (1) | SA516371223B1 (enExample) |
| WO (1) | WO2015081155A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9889194B2 (en) | 2013-03-01 | 2018-02-13 | New York Blood Center, Inc. | Immunogenic composition for MERS coronavirus infection |
| KR20230122181A (ko) * | 2013-11-29 | 2023-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 |
| US11103575B2 (en) | 2014-02-28 | 2021-08-31 | The New York Blood Center, Inc. | Immunogenic composition for MERS coronavirus infection |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| US11058779B2 (en) | 2015-09-08 | 2021-07-13 | Sirnaomics, Inc. | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection |
| EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
| CN106397549B (zh) * | 2016-10-11 | 2019-08-06 | 中国疾病预防控制中心病毒病预防控制所 | MERS-CoV特异性多肽及其应用 |
| CA3040540A1 (en) | 2016-11-10 | 2018-05-17 | Oyagen, Inc. | Methods of treating and inhibiting ebola virus infection |
| KR20180058206A (ko) * | 2016-11-23 | 2018-05-31 | 에스케이케미칼 주식회사 | 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법 |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2019078600A1 (ko) * | 2017-10-19 | 2019-04-25 | (주)에이티젠 | 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법 |
| WO2021158248A1 (en) | 2020-02-04 | 2021-08-12 | Oyagen, Inc. | Method for treating coronavirus infections |
| PH12022552249A1 (en) * | 2020-02-25 | 2023-11-13 | Inovio Pharmaceuticals Inc | Vaccines against coronavirus and methods of use |
| CN111378785A (zh) * | 2020-03-12 | 2020-07-07 | 仁宽(上海)生物科技有限公司 | 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用 |
| US11559577B2 (en) | 2020-03-31 | 2023-01-24 | Engimata, Inc. | Immunogenic composition forming a vaccine, and a method for its manufacture |
| WO2021225344A1 (ko) * | 2020-05-08 | 2021-11-11 | 한림대학교 산학협력단 | 코로나 바이러스 억제용 펩타이드 및 그 용도 |
| CN115867313A (zh) * | 2020-05-12 | 2023-03-28 | 格雷菲克斯公司 | 作为疫苗抗原的工程化冠状病毒刺突蛋白、其设计和用途 |
| WO2021252604A1 (en) * | 2020-06-09 | 2021-12-16 | The Wistar Institute Of Anatomy And Biology | Coronavirus disease 2019 (covid-19) combination vaccine |
| EP4178545A4 (en) * | 2020-07-10 | 2024-08-07 | Engimata, Inc | IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF |
| WO2022020604A1 (en) * | 2020-07-22 | 2022-01-27 | Greffex, Inc. | Multivalent beta-coronavirus vaccines, their design and uses |
| WO2022025029A1 (ja) * | 2020-07-27 | 2022-02-03 | 国立大学法人滋賀医科大学 | ｉｎ ｖｉｔｒｏにおいてコロナウイルス科に属するウイルスを増殖させる方法、コロナウイルス科に属するウイルスに対する中和抗体の産生方法、及びＳｅｖｅｒｅ ａｃｕｔｅ ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｄｒｏｍｅ ｃｏｒｏｎａｖｉｒｕｓ ２の感染モデルの製造方法 |
| EP4196158A1 (en) * | 2020-08-14 | 2023-06-21 | Julius-Maximilians-Universität Würzburg | Salmonella vaccine for the treatment of coronavirus |
| WO2022046737A1 (en) * | 2020-08-25 | 2022-03-03 | The Wistar Institute Of Anatomy And Biology | Intradermal mers-cov vaccine |
| WO2022051816A1 (en) * | 2020-09-10 | 2022-03-17 | The Council Of The Queensland Institute Of Medical Research | Methods of determining immune response |
| WO2022056302A1 (en) * | 2020-09-11 | 2022-03-17 | Memgen, Inc. | Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine |
| EP4333887A4 (en) * | 2021-05-05 | 2025-05-21 | Inovio Pharmaceuticals, Inc. | Vaccines against coronavirus and methods of use |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| US3805783A (en) | 1971-02-12 | 1974-04-23 | A Ismach | Hand powered hypodermic jet injector gun |
| US4342310A (en) | 1980-07-08 | 1982-08-03 | Istvan Lindmayer | Hydro-pneumatic jet injector |
| US4447223A (en) | 1982-04-16 | 1984-05-08 | Cct Associates | Medicament implant applicator |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5505697A (en) | 1994-01-14 | 1996-04-09 | Mckinnon, Jr.; Charles N. | Electrically powered jet injector |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6009347A (en) | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| JP2002520101A (ja) | 1998-07-13 | 2002-07-09 | ジェネトロニクス、インコーポレーテッド | 電気的に補助される化粧用薬剤の局部送達法および装置 |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
| US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| US6520950B1 (en) | 1999-05-10 | 2003-02-18 | Genetronics, Inc. | Method of electroporation-enhanced delivery of active agents |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| WO2005017133A1 (en) * | 2003-08-18 | 2005-02-24 | Amsterdam Institute Of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| CN101098710A (zh) * | 2004-06-02 | 2008-01-02 | 纽约血液中心 | 产生高度有效抗体的sars疫苗和方法 |
| EP1766073A4 (en) * | 2004-06-04 | 2007-08-01 | Wyeth Corp | IMPROVING PROTEIN EXPRESSION |
| US7553944B2 (en) * | 2004-07-21 | 2009-06-30 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
| JP5852883B2 (ja) * | 2008-08-08 | 2016-02-03 | タケダ ワクチン，インコーポレイテッド | 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子 |
| CN103476928B (zh) * | 2010-12-09 | 2017-03-29 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
| EP2788478B1 (en) | 2011-12-09 | 2017-08-23 | Institut Pasteur | Multiplex immuno screening assay |
| EP2876161B1 (en) * | 2012-07-23 | 2018-12-05 | The Institute of Biological Resources | Vaccine |
| SG11201601423SA (en) | 2013-09-19 | 2016-04-28 | Novavax Inc | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| KR20230122181A (ko) * | 2013-11-29 | 2023-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 |
-
2014
- 2014-11-26 KR KR1020237027157A patent/KR20230122181A/ko not_active Ceased
- 2014-11-26 AU AU2014354797A patent/AU2014354797C1/en active Active
- 2014-11-26 CA CA2932055A patent/CA2932055A1/en active Pending
- 2014-11-26 JP JP2016534936A patent/JP6412131B2/ja active Active
- 2014-11-26 IL IL276210A patent/IL276210B2/en unknown
- 2014-11-26 IL IL305392A patent/IL305392A/en unknown
- 2014-11-26 EP EP14866748.8A patent/EP3074051A4/en not_active Withdrawn
- 2014-11-26 WO PCT/US2014/067537 patent/WO2015081155A1/en not_active Ceased
- 2014-11-26 CN CN201480074433.XA patent/CN105939730B/zh active Active
- 2014-11-26 US US15/039,672 patent/US10016497B2/en active Active
- 2014-11-26 KR KR1020167015308A patent/KR20160091350A/ko not_active Ceased
- 2014-11-26 CN CN202010825164.3A patent/CN112057613A/zh active Pending
-
2016
- 2016-05-29 IL IL245903A patent/IL245903B/en active IP Right Grant
- 2016-05-29 SA SA516371223A patent/SA516371223B1/ar unknown
-
2018
- 2018-06-29 US US16/022,839 patent/US10548971B2/en active Active
-
2020
- 2020-02-04 US US16/781,433 patent/US11135284B2/en not_active Expired - Fee Related
-
2021
- 2021-09-10 US US17/472,003 patent/US11801298B2/en active Active
-
2023
- 2023-09-28 US US18/476,921 patent/US20240123056A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| F. SONG ET AL,, MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS SPIKE PROTEIN DELIVERED BY MODIFIED VACCINIA VIRUS ANKARA EFFICIENTLY INDUCES VIRUS-NEUTRALIZING ANTIBODIES, 1 November 2013 (2013-11-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200222527A1 (en) | 2020-07-16 |
| EP3074051A1 (en) | 2016-10-05 |
| CA2932055A1 (en) | 2015-06-04 |
| US10016497B2 (en) | 2018-07-10 |
| US20190022213A1 (en) | 2019-01-24 |
| JP6412131B2 (ja) | 2018-10-24 |
| IL276210B1 (en) | 2023-09-01 |
| AU2014354797A1 (en) | 2016-07-07 |
| US10548971B2 (en) | 2020-02-04 |
| US20240123056A1 (en) | 2024-04-18 |
| WO2015081155A1 (en) | 2015-06-04 |
| US20210401972A1 (en) | 2021-12-30 |
| JP2016539946A (ja) | 2016-12-22 |
| CN112057613A (zh) | 2020-12-11 |
| EP3074051A4 (en) | 2017-04-12 |
| KR20230122181A (ko) | 2023-08-22 |
| AU2014354797B2 (en) | 2017-10-26 |
| US11801298B2 (en) | 2023-10-31 |
| AU2014354797C1 (en) | 2018-02-01 |
| CN105939730B (zh) | 2020-09-11 |
| SA516371223B1 (ar) | 2023-01-31 |
| US11135284B2 (en) | 2021-10-05 |
| KR20160091350A (ko) | 2016-08-02 |
| IL245903B (en) | 2020-08-31 |
| IL305392A (en) | 2023-10-01 |
| US20170258893A1 (en) | 2017-09-14 |
| IL276210A (en) | 2020-09-30 |
| IL245903A0 (en) | 2016-07-31 |
| CN105939730A (zh) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276210B2 (en) | Mers-cov vaccine | |
| JP2016539946A5 (enExample) | ||
| EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| WO2008039408A3 (en) | Live bacterial vaccines for viral infection prophylaxis or treatment | |
| JP2014534202A5 (enExample) | ||
| MX2018012095A (es) | Vacuna contra vrs. | |
| JP2015214545A5 (enExample) | ||
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| CL2008002559A1 (es) | Construccion que comprende un vector de fluorocarbono y un antigeno del virus de la influenza; composicion farmaceutica que lo comprende; y su uso para aumentar la respuesta inmunologica | |
| NZ597858A (en) | Vaccines and compositions against streptococcus pneumoniae | |
| WO2010037027A3 (en) | Immunization of avians by mucosal administration of non-replicating vectored vaccines | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| RU2018116601A (ru) | Иммунногенный слитый белок | |
| WO2011094357A8 (en) | Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization | |
| FI3220937T3 (fi) | Pneumolysiinimutantteja ja menetelmiä niiden käyttämiseksi | |
| CA3010977A1 (en) | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus | |
| AU2014232363A8 (en) | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| MX2022003590A (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9. | |
| AR095425A1 (es) | Vacuna, uso y procedimiento para prevenir una infección por picornavirus | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| JP2019534242A5 (enExample) |